Anixa Biosciences (ANIX) Projected to Post Quarterly Earnings on Tuesday

Anixa Biosciences (NASDAQ:ANIX) is projected to issue its quarterly earnings data before the market opens on Tuesday, January 21st. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. On average, analysts expect Anixa Biosciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Anixa Biosciences Stock Performance

Shares of ANIX traded up $0.15 during trading hours on Wednesday, hitting $2.28. 304,351 shares of the company were exchanged, compared to its average volume of 102,889. The company has a market cap of $73.37 million, a PE ratio of -5.85 and a beta of 0.82. The firm’s 50 day moving average is $2.86 and its 200-day moving average is $3.03. Anixa Biosciences has a 52 week low of $2.07 and a 52 week high of $5.13.

Analysts Set New Price Targets

ANIX has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday, November 19th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday.

Insider Activity at Anixa Biosciences

In other Anixa Biosciences news, CEO Amit Kumar bought 43,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was purchased at an average price of $2.23 per share, for a total transaction of $95,890.00. Following the purchase, the chief executive officer now directly owns 559,925 shares in the company, valued at $1,248,632.75. This trade represents a 8.32 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 22.60% of the stock is owned by corporate insiders.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.